Title: Creation of the Paradict-O center in orleans to prevent maternal drug toxicity in breastfed neonate

Biography:

Serreau Raphael, started pharmacology in 1997. Upon completion of his doctorate in Pharmacology at the University of Paris V Rene Descartes in 2007 about Risk Management Plan during pregnancy and breastfeeding, Pr Raphal Serreau joined the Center of Clinical Research in Cochin and Necker Hospital in Paris where he directed research combining Perinatology and Pharmacology. (www.premup.org). He worked also in Necker University in EA 3620 “VIH Child-Mother Unit”. In 2012 with Prof Tabassome Simon (St Antoine Hospital, Paris), Prof Robert Barouki (Necker Hospital, Paris) and Jean-Luc Volatier (ANSES, Maisons-Alfort), Prof Serreau obtained a grant for his research fields about contaminants and breast milk. He‘s team got half million euros to do contalait study. 180 women were included in 6 milk banks in France (Lyon, Paris, Lille, Montpellier, Bordeaux and Nantes) during 18 months. Heavy metals,  PCB, furans, dioxins and different contaminants were dosed in breast milk. Tuna Fish consumption and dental filling were responsible of high methyl mercury concentrations in breast milk.  Contaminants should be assess regularly in lactating women. In 2019 Prof Raphael Serreau became Director of PARADICT-O center in Orleans Metropole and his team reach the EA INSERM Psycomadd in AP-HP 6 University of Paris Saclay (Prof Amine Benyamina).

Abstract

We studied ibuprofen and ketoprofen, drugs of the class of NSAIDs (profen) at risk during pregnancy. We performed the assays in colostral milk and mature breast milk to verify its compatibility during breastfeeding. The study included 20 breastfeeding mothers, treated orally by a minimum of 3 x 200 mg tablets of ibuprofen in order to reach steady state at least on the 7th day after the delivery. Ibuprofen half-life (t1/2) is previously documented in the literature 114 minutes21. Steady state concentration is achieved when ibuprofen is administered at a constant rate (5 x t1/2 ~ 10 hours), at a minimum of 3 tablets/day of 200 mg ibuprofen.

Women included in our study were among those who seeked information on the compatibility of ibuprofen and breastfeeding by contacting the Medic-Al network. Women below 18 years of age and/or treated by naproxen and/or who have not given their informed written consent were excluded. This study took place from the 1st of January 2011 till the 30th of September 2012.

We want to offer breast milk as a occupationnal medicine health matrix that would be suitable for monitoring the effects of toxins as endocrine disruptors. A network of pharmacologists and perinatology toxicologists should make it possible to optimize the pursuit of knowledge in this still little studied field. For this purpose, the "PARADICT-O" Department of Preventive Medicine was created on January 28, 2018 in Orleans to continue the pharmacological research activities set up with the "Médic-Al" network in Paris.